quinon
secondari
metabolit
higher
plant
associ
mani
biolog
activ
includ
antivir
effect
cytotox
studi
antiherpet
antidengu
evalu
nq
aq
heterocyclefus
quinon
hetq
deriv
done
vitro
human
herpesviru
hhv
type
dengu
viru
serotyp
cytotox
hela
jurkat
tumor
cell
line
also
test
use
plaqu
form
unit
assay
cell
viabil
assay
molecular
dock
found
nq
best
antivir
compound
aq
activ
select
molecul
test
tumor
cell
nq
show
fair
antivir
activ
herpesvirus
ec
preinfect
stage
addit
nq
disrupt
viral
attach
vero
cell
ec
high
select
index
si
silico
analysi
predict
quinon
could
bind
prefus
form
e
glycoprotein
find
demonstr
nq
potent
highli
select
antivir
compound
suggest
abil
prevent
herp
dengu
infect
addit
aq
consid
interest
leader
design
new
anticanc
agent
recent
year
treatment
control
viral
agent
becom
major
challeng
pharmaceut
industri
due
pathophysiolog
featur
develop
drugresist
among
human
herpesvirus
type
associ
cold
sore
herp
genitali
respect
neurotrop
neuroinvas
doublestrand
dna
dsdna
quinon
deriv
prepar
initi
dielsald
cycloaddit
reaction
myrcen
pbenzoquinon
follow
appropri
transform
previous
describ
us
compound
includ
studi
select
repres
member
three
famili
hetq
structur
repres
tabl
figur
tabl
structur
nq
aq
deriv
test
vitro
antivir
evalu
substanc
human
herpesviru
type
made
infect
vero
cell
use
endpoint
titrat
techniqu
eptt
compound
show
fair
reduct
viral
titer
concentr
h
consid
activ
tabl
show
reduct
valu
viral
titer
rf
antivir
activ
nq
aq
hetq
activ
least
one
viru
serotyp
vitro
antivir
evalu
substanc
human
herpesviru
type
made
infect
vero
cell
use
endpoint
titrat
techniqu
eptt
compound
show
fair
reduct
viral
titer
concentr
h
consid
activ
tabl
show
reduct
valu
viral
titer
rf
antivir
activ
nq
aq
hetq
activ
least
one
viru
serotyp
vitro
antivir
evalu
substanc
human
herpesviru
type
made
infect
vero
cell
use
endpoint
titrat
techniqu
eptt
compound
show
fair
reduct
viral
titer
concentr
h
consid
activ
tabl
show
reduct
valu
viral
titer
rf
antivir
activ
nq
aq
hetq
activ
least
one
viru
serotyp
vitro
antivir
evalu
substanc
human
herpesviru
type
made
infect
vero
cell
use
endpoint
titrat
techniqu
eptt
compound
show
fair
reduct
viral
titer
concentr
h
consid
activ
tabl
show
reduct
valu
viral
titer
rf
antivir
activ
nq
aq
hetq
activ
least
one
viru
serotyp
tabl
reduct
viral
titer
antivir
activ
human
herpesviru
type
infect
vero
cell
select
nq
aq
accord
estim
vlietinck
et
al
purifi
natur
molecul
consid
relev
moder
antivir
activ
reduct
factor
rf
viral
titer
respect
studi
defin
rf
mild
moder
activ
substanc
respect
shown
tabl
total
thirteen
compound
activ
nq
aq
show
mild
activ
rf
concentr
aq
show
rf
valu
concentr
nq
mildli
activ
aq
nq
aq
show
moder
effect
rf
except
nq
attain
rf
concentr
moder
antivir
activ
rf
also
found
nq
aq
concentr
respect
result
reveal
gener
potent
antiherpet
substanc
nq
quinon
show
moder
antiherpet
activ
serotyp
suggest
wide
spectrum
antivir
activ
molecul
chemic
point
view
presenc
one
two
chlorin
atom
quinon
ring
nq
aq
contribut
enhanc
antivir
activ
featur
probabl
correl
broad
spectrum
activ
substanc
also
accord
previou
studi
chlorin
quinon
also
show
signific
antifung
activ
gener
note
molecul
test
effect
mainli
tabl
fact
relat
molecular
natur
compound
dose
infecti
viru
employ
assay
nonetheless
import
note
hhv
serotyp
use
differ
cellular
receptor
attach
enter
host
notabl
receptor
avail
infect
featur
disadvantag
consid
also
greater
number
bind
site
access
antivir
agent
thu
lead
possibl
disrupt
viral
entri
subsequ
replic
step
defin
stage
viral
replic
cycl
nq
exert
action
simultan
postinfect
treatment
perform
addit
experi
also
extend
prove
potenti
antivir
broadspectrum
nq
figur
first
determin
inhibitori
concentr
ic
compound
drug
posit
control
infect
cell
effect
nontumor
vero
cell
defin
concentr
evalu
calcul
antivir
select
index
si
concentr
nq
reduc
number
viral
plaqu
ec
determin
doserespons
curv
studi
consid
molecul
interest
antivir
select
si
ic
ec
valu
vero
cell
nq
show
ic
valu
antivir
control
dextran
sulfat
ds
heparin
h
acyclovir
ribavirin
r
show
ic
valu
r
data
shown
simultan
treatment
nq
show
antiherpet
activ
concentr
test
signific
manner
p
valu
figur
figur
thu
possibl
calcul
doserespons
curv
antivir
si
expect
dextran
sulfat
posit
control
activ
figur
nq
evalu
lower
concentr
hhv
serotyp
show
signific
antivir
activ
p
valu
effect
compar
display
posit
control
heparin
postinfect
stage
nq
show
activ
neither
howev
posit
control
acyclovir
ribavirin
employ
hhv
serotyp
respect
activ
result
suggest
nq
produc
antivir
effect
earli
stage
infecti
cycl
ie
attach
andor
viral
entri
defin
stage
viral
replic
cycl
nq
exert
action
simultan
postinfect
treatment
perform
addit
experi
also
extend
prove
potenti
antivir
broadspectrum
nq
figur
first
determin
inhibitori
concentr
compound
drug
posit
control
infect
cell
effect
nontumor
vero
cell
defin
concentr
evalu
calcul
antivir
select
index
si
concentr
nq
reduc
number
viral
plaqu
determin
doserespons
curv
studi
consid
molecul
interest
antivir
select
si
valu
vero
cell
nq
show
valu
antivir
control
dextran
sulfat
ds
heparin
h
acyclovir
ribavirin
r
show
valu
r
data
shown
simultan
treatment
nq
show
antiherpet
activ
concentr
test
signific
manner
p
valu
figur
figur
thu
possibl
calcul
doserespons
curv
antivir
si
expect
dextran
sulfat
posit
control
activ
figur
nq
evalu
lower
concentr
hhv
serotyp
show
signific
antivir
activ
p
valu
effect
compar
display
posit
control
heparin
postinfect
stage
nq
show
activ
neither
howev
posit
control
acyclovir
ribavirin
employ
hhv
serotyp
respect
activ
result
suggest
nq
produc
antivir
effect
earli
stage
infecti
cycl
ie
attach
andor
viral
entri
prove
hypothesi
evalu
nq
exert
effect
attach
revers
interact
viral
glycoprotein
cellular
receptor
occur
viral
entri
membran
fusion
viru
intern
happen
take
account
high
activ
molecul
simultan
treatment
lower
concentr
nq
employ
assay
perform
consid
mention
serotyp
use
cellular
receptor
attach
entri
result
show
nq
reduc
significantli
p
attach
vero
cell
si
compar
ds
dmso
control
meanwhil
effect
compound
viral
entri
signific
figur
report
indic
make
initi
contact
host
cell
bind
glycosaminoglycan
receptor
heparan
sulfat
interact
revers
necessari
c
prove
hypothesi
evalu
nq
exert
effect
attach
revers
interact
viral
glycoprotein
cellular
receptor
occur
viral
entri
membran
fusion
viru
intern
happen
take
account
high
activ
molecul
simultan
treatment
lower
concentr
nq
employ
assay
perform
consid
mention
serotyp
use
cellular
receptor
attach
entri
result
show
nq
reduc
significantli
p
attach
vero
cell
ec
si
compar
ds
dmso
control
meanwhil
effect
compound
viral
entri
signific
figur
prove
hypothesi
evalu
nq
exert
effect
attach
revers
interact
viral
glycoprotein
cellular
receptor
occur
viral
entri
membran
fusion
viru
intern
happen
take
account
high
activ
molecul
simultan
treatment
lower
concentr
nq
employ
assay
perform
consid
mention
serotyp
use
cellular
receptor
attach
entri
result
show
nq
reduc
significantli
p
attach
vero
cell
si
compar
ds
dmso
control
meanwhil
effect
compound
viral
entri
signific
figur
report
indic
make
initi
contact
host
cell
bind
glycosaminoglycan
receptor
heparan
sulfat
interact
revers
necessari
c
report
indic
make
initi
contact
host
cell
bind
glycosaminoglycan
receptor
heparan
sulfat
interact
revers
necessari
viru
locat
cell
surfac
thu
allow
bind
viral
ligand
specif
receptor
addit
describ
exist
differ
way
hhv
entri
cell
includ
low
phdepend
independ
endocytosi
fusion
plasma
membran
even
though
viral
entri
pathway
celltyp
depend
note
glycoprotein
gb
gd
ghgl
requir
entri
pathway
recent
year
antivir
activ
describ
certain
quinon
structur
relat
molecul
therapeut
potenti
nq
aq
shown
antivir
activ
dna
rna
virus
inhibit
viral
entri
replic
genom
transcript
well
affect
function
import
enzym
viral
replic
cycl
emodin
isol
root
rheum
tanguticum
show
vitro
vivo
antiherpet
activ
affect
viral
replic
ie
late
stage
infecti
cycl
likewis
antivir
mechan
describ
quinon
includ
inhibit
protein
relat
uncoat
dna
process
inhibit
enzym
involv
viral
protein
phosphoryl
casein
kinas
moreov
denbinobin
phenanthrenequinon
report
dual
inhibitor
ltr
promot
transcript
factor
nfkb
affect
viral
transcript
result
demonstr
nq
act
select
earli
infect
stage
strain
specif
viral
attach
suggest
nq
mainli
disrupt
interact
viral
glycoprotein
glycosaminoglycan
receptor
therefor
viral
entri
would
partial
affect
figur
antivir
approach
attract
step
mandatori
success
viral
infect
reinforc
hypothet
mode
action
nq
attach
entri
molecular
dock
analysi
compound
bind
cleft
envelop
protein
env
prefus
form
run
base
cocrystal
complex
determin
potenti
pocket
site
discoveri
smallmolecul
fusion
inhibitor
pocket
sever
amino
acid
report
critic
membran
fusion
viru
entri
among
studi
show
nq
fit
aliphat
substructur
bind
cleft
dengu
viru
e
glycoprotein
dimer
predict
score
kcalmol
molecul
form
key
hydrogen
bond
set
hydrophob
interact
within
cleft
figur
accord
predict
mode
action
enthalp
contribut
mostli
govern
hydrophob
interact
posit
induc
prefer
opposit
orient
two
chlorin
atom
molecul
x
peer
review
possibl
propos
nq
act
similar
way
probabl
affect
entri
rather
attach
found
antivir
activ
sever
quinon
herpesvirus
late
stage
infect
report
studi
found
differ
kind
antivir
effect
quinon
show
nq
exert
activ
earli
stage
specif
avoid
viral
attach
understand
impact
interact
also
dock
anthracyclin
antibiot
doxorubicin
drug
evalu
kaptein
et
al
togeth
doxorubicin
deriv
squaric
acid
amid
ester
moieti
carbohydr
group
activ
low
concentr
earli
stage
viral
replic
cycl
ie
viru
attach
andor
viru
entri
treatment
timeofaddit
studi
reveal
concentr
drug
attain
inhibit
viru
replic
ad
first
hour
infect
respect
addit
compound
fail
effici
inhibit
viral
replic
ad
h
postinfect
inhibit
rna
replic
use
bind
site
env
protein
kaptein
et
al
report
molecular
dock
studi
form
hydrogen
bond
amino
acid
hydrophob
contact
critic
membran
fusion
viru
entri
case
found
doxorubicin
form
hydrogen
bond
display
interact
figur
molecul
fit
part
structur
bind
cleft
dengu
viru
e
glycoprotein
dimer
similar
lower
score
kcalmol
nq
howev
interact
form
amino
acid
found
nq
report
consid
inform
possibl
propos
nq
act
similar
way
probabl
affect
entri
rather
attach
found
antivir
activ
sever
quinon
herpesvirus
late
stage
infect
report
studi
found
differ
kind
antivir
effect
quinon
show
nq
exert
activ
earli
stage
specif
avoid
viral
attach
compound
possibl
disrupt
entri
quinon
deriv
may
affect
dramat
phospholipid
membran
may
respons
remark
chang
physic
biolog
properti
alter
might
consist
chang
lipidwat
interfac
neg
charg
phospholipid
disrupt
core
lipid
bilay
report
may
consist
find
consid
lipid
membran
reconfigur
caus
type
quinon
may
affect
initi
interact
viruscellular
receptor
subsequ
viral
entri
host
cell
inde
basi
predict
logp
clogp
valu
low
tpsa
total
polar
surfac
area
valu
estim
chemdraw
algorithm
nq
membran
affin
appear
fairli
support
howev
addit
experi
necessari
confirm
refus
mechanist
hypothesi
nq
aq
hetq
test
evalu
vitro
cytotox
tumor
hela
jurkat
nontumor
vero
cell
common
anticanc
drug
doxorubicin
includ
assay
refer
seen
tabl
molecul
cytotox
least
one
cancer
cell
line
result
obtain
gener
consider
made
three
group
quinon
test
analyz
result
consid
compound
ic
good
cytotox
neoplast
cell
ic
valu
moder
cytotox
ic
valu
correspond
low
null
activ
addit
sever
recent
studi
defin
select
index
si
valu
respect
cell
consid
indic
potenti
therapeut
use
anticanc
agent
si
valu
serv
criterion
work
defin
select
anticanc
substanc
gener
observ
aq
cytotox
nq
show
better
result
hetq
accord
previou
studi
among
nq
presenc
halogen
quinon
ring
improv
cytotox
cancer
normal
cell
aq
group
arylamino
substitu
induc
higher
select
lead
best
neoplast
cytotox
low
toxic
normal
cell
within
group
hetq
imidazolefus
hetq
quinon
highest
vitro
cytotox
hela
cell
aq
bear
pmethoxyphenylamino
substitu
show
lowest
ic
valu
nm
best
si
valu
near
respect
vero
cell
much
better
refer
drug
doxorubicin
addit
aq
cytotox
hela
cell
ic
valu
display
si
valu
respect
si
also
observ
dichlorin
nq
though
rang
low
cytotox
ic
jurkat
cell
aq
show
high
cytotox
relev
si
valu
follow
nq
aq
show
ic
valu
respect
though
moder
low
si
valu
respect
addit
aq
aq
quinon
fair
cytotox
hela
jurkat
cell
lower
concentr
final
accord
si
valu
aq
select
compound
type
cancer
cell
unlik
nq
deriv
must
note
addit
high
select
toward
cancer
cell
aq
also
show
interest
select
depend
type
cancer
result
time
potent
hela
jurkat
cell
figur
fact
also
defin
qualit
differ
respect
doxorubicin
invers
result
much
less
select
ten
time
cytotox
jurkat
hela
cell
respect
doxorubicin
invers
result
much
less
select
ten
time
cytotox
jurkat
hela
cell
aim
obtain
valid
aq
structur
submit
onlin
predict
screen
get
data
druggabl
potenti
therefor
examin
predict
algorithm
molinspir
virtual
screen
engin
aq
qualifi
potenti
kinas
inhibitor
score
potenti
nuclear
receptor
ligand
recogn
probabl
intrins
bioactiv
examin
osiri
properti
explor
addit
physicochem
data
like
mw
clogp
valu
within
permit
lipinski
rule
five
reveal
aq
potenti
exempt
carcinogen
mutagen
irrit
reproduct
cycl
effect
devoid
main
advers
effect
experiment
fact
calcul
predict
data
support
select
aq
carri
mechanist
studi
target
definit
structur
optim
orient
configur
preclin
toxic
efficaci
assay
among
mechan
action
quinon
differ
tumor
type
report
decreas
mitochondri
membran
potenti
rosmedi
pathway
arrest
downregul
regulatori
protein
cyclin
dna
damag
induct
doublestrand
break
inhibit
topoisomeras
ii
glutathion
deplet
addit
quinon
moieti
present
clinic
use
anticanc
agent
mitomycin
c
doxorubicin
mitomycin
c
use
treatment
gastrointestin
tumor
act
doublestrand
dna
alkyl
agent
doxorubicin
commonli
use
cancer
treatment
includ
breast
lung
gastric
carcinoma
among
act
dna
intercal
agent
gener
free
radic
damag
cellular
membran
dna
protein
fact
exampl
clinic
use
drug
demonstr
potenti
quinon
deriv
antitumor
agent
furthermor
result
suggest
cell
death
induc
aq
aq
aq
could
involv
one
abovement
mechan
action
even
differ
one
consequ
addit
studi
requir
establish
proper
cytotox
mechan
aq
nq
obtain
previous
describ
procedur
aq
also
obtain
describ
nq
aq
obtain
describ
previous
hetq
obtain
describ
previous
aim
obtain
valid
aq
structur
submit
onlin
predict
screen
get
data
druggabl
potenti
therefor
examin
predict
algorithm
molinspir
virtual
screen
engin
aq
qualifi
potenti
kinas
inhibitor
score
potenti
nuclear
receptor
ligand
recogn
probabl
intrins
bioactiv
examin
osiri
properti
explor
addit
physicochem
data
like
mw
clogp
valu
within
permit
lipinski
rule
five
reveal
aq
potenti
exempt
carcinogen
mutagen
irrit
reproduct
cycl
effect
devoid
main
advers
effect
experiment
fact
calcul
predict
data
support
select
aq
carri
mechanist
studi
target
definit
structur
optim
orient
configur
preclin
toxic
efficaci
assay
among
mechan
action
quinon
differ
tumor
type
report
decreas
mitochondri
membran
potenti
rosmedi
pathway
arrest
downregul
regulatori
protein
cyclin
dna
damag
induct
doublestrand
break
inhibit
topoisomeras
ii
glutathion
deplet
addit
quinon
moieti
present
clinic
use
anticanc
agent
mitomycin
c
doxorubicin
mitomycin
c
use
treatment
gastrointestin
tumor
act
doublestrand
dna
alkyl
agent
doxorubicin
commonli
use
cancer
treatment
includ
breast
lung
gastric
carcinoma
among
act
dna
intercal
agent
gener
free
radic
damag
cellular
membran
dna
protein
fact
exampl
clinic
use
drug
demonstr
potenti
quinon
deriv
antitumor
agent
furthermor
result
suggest
cell
death
induc
aq
aq
aq
could
involv
one
abovement
mechan
action
even
differ
one
consequ
addit
studi
requir
establish
proper
cytotox
mechan
aq
nq
obtain
previous
describ
procedur
aq
also
obtain
describ
nq
aq
obtain
describ
previous
hetq
obtain
describ
previous
antivir
activ
molecul
cell
cultur
infecti
dose
respect
determin
use
endpoint
titrat
techniqu
eptt
vero
cell
grown
plate
densiti
cellswel
incub
c
co
atmospher
constitut
cell
monolay
viral
suspens
concentr
compound
perform
dmem
supplement
fb
contain
carboxymethylcellulos
cmc
respect
mixtur
incub
minut
room
temperatur
ad
cell
monolay
h
incub
c
co
cytopath
effect
examin
micropl
fix
formaldehyd
stain
crystal
violet
two
independ
experi
quadrupl
viral
serotyp
carri
posit
control
dextran
sulfat
ds
acyclovir
earli
stage
late
stage
infect
respect
includ
potenti
antivir
mechan
nq
evalu
plaqu
reduct
assay
previous
describ
us
vero
cell
monolay
grown
plate
infect
pfuwel
viru
simultan
treatment
compound
viru
ad
simultan
cell
monolay
incub
h
c
co
cell
wash
phosphat
buffer
salin
pb
ph
cmc
ad
respect
postinfect
treatment
viru
ad
cell
monolay
incub
h
c
co
incub
wash
perform
pb
molecul
previous
prepar
cmc
respect
ad
treatment
nq
prepar
concentr
cell
monolay
allow
incub
h
subsequ
cell
fix
stain
solut
formaldehyd
crystal
violet
viral
plaqu
count
dextran
sulfat
ds
includ
posit
control
simultan
assay
acyclovir
posit
control
infect
treatment
denv
effect
nq
either
simultan
postinfect
also
evalu
plaqu
reduct
assay
previous
describ
concentr
employ
assay
test
cell
monolay
grown
plate
infect
pfuwel
treatment
perform
way
describ
herpesvirus
moreov
monolay
incub
day
fix
stain
solut
formaldehyd
crystal
violet
viral
plaqu
count
heparin
h
includ
posit
control
simultan
assay
ribavirin
r
posit
control
infect
treatment
effect
nq
initi
phase
viral
replic
done
previous
describ
cardozo
et
al
attach
assay
prechil
h
c
vero
cell
monolay
expos
virus
pfuwel
presenc
absenc
compound
incub
h
c
incub
substanc
unbound
virus
remov
cold
pb
cell
overlaid
cmc
incub
h
c
co
entri
assay
prechil
cell
infect
virus
pfuwel
incub
h
c
time
unbound
virus
remov
cold
pb
cell
treat
differ
concentr
prewarm
compound
incub
h
c
unabsorb
virus
inactiv
use
citrat
buffer
ph
cell
wash
pb
overlaid
cmc
incub
h
c
co
assay
procedur
mention
previous
plaqu
reduct
assay
dextran
sulfat
ds
includ
posit
control
test
evalu
nq
concentr
rang
effect
concentr
fifti
ec
concentr
reduc
plaqu
form
unit
determin
doseeffect
curv
linear
regress
method
compound
ec
valu
express
mean
sem
standard
error
mean
least
four
dilut
quadrupl
addit
determin
nq
select
infect
cell
rather
uninfect
cell
calcul
antivir
select
index
si
defin
ratio
inhibitori
concentr
ic
vero
cell
ec
viru
parametr
ligand
nq
doxorubicin
prefus
envelop
protein
done
use
autodock
tool
suit
hydrogen
atom
ad
polar
side
chain
partial
charg
calcul
gasteig
methodolog
grid
box
delimit
bind
site
previous
report
studi
inhibitor
molecular
dock
run
modifi
version
autodock
vina
includ
score
function
parameter
also
halogen
interact
use
exhaust
number
intern
repetit
proteincompound
pair
interact
hydrogen
bond
hydrophob
interact
predict
free
energi
score
kcalmol
obtain
visual
dock
result
gener
use
discoveri
studio
packag
vitro
cytotox
evalu
quinon
perform
use
bromid
mtt
sigma
cream
ridg
nj
usa
assay
describ
betancurgalvi
et
al
briefli
vero
hela
cell
line
seed
cell
per
well
plate
dmem
supplement
inactiv
fb
incub
h
c
co
dilut
molecul
ad
cell
incub
h
c
co
jurkat
cell
line
cell
per
well
roundbottom
plate
dilut
substanc
medium
sigma
supplement
fb
plate
simultan
h
treatment
c
co
media
care
remov
mtt
solut
mgml
ad
well
plate
incub
h
c
co
dmso
ad
dissolv
form
formazan
crystal
absorb
determin
spectrophotometr
nm
minim
dilut
compound
caus
inhibit
cell
ic
calcul
linear
regress
analysi
doserespons
curv
gener
absorb
data
statist
graphpad
prisma
ic
valu
express
mean
standard
deviat
sd
two
independ
experi
done
quadrupl
defin
molecul
select
cancer
cell
select
index
si
defin
vero
ic
hela
jurkat
ic
valu
calcul
statist
analys
perform
use
statist
softwar
graphpad
graphpad
softwar
inc
la
jolla
ca
usa
case
p
valu
statist
signific
current
necessari
discov
new
better
antivir
novel
mechan
action
treatment
human
herpesviru
type
infect
mainli
treatment
immunocompromis
transplant
patient
consid
continu
emerg
hhv
acyclovirresist
strain
moreov
discov
medicin
dengu
diseas
imper
take
account
impact
diseas
public
health
studi
naphthoquinon
nq
shown
import
antiherpet
ec
antidengu
activ
earli
infect
stage
mainli
initi
format
complex
viral
glycoprotein
host
cell
surfac
receptor
therebi
prevent
event
relat
fusion
subsequ
viral
genom
replic
product
new
virion
addit
nq
disrupt
viral
attach
vero
cell
ec
high
select
index
si
silico
analysi
perform
nq
predict
could
bind
prefus
form
e
glycoprotein
context
find
start
point
follow
biopharmaceut
preclin
toxic
efficaci
evalu
focus
toward
develop
formul
pharmaceut
product
prevent
herp
dengu
infect
avoid
appear
new
drugresist
strain
relat
potenti
quinon
antineoplast
anthraquinon
aq
cytotox
either
hela
ic
jurkat
ic
cell
line
low
toxic
vero
cell
ic
therefor
high
si
much
better
refer
drug
doxorubicin
fact
make
aq
new
highli
select
promis
lead
compound
due
experiment
result
found
also
favor
physicochem
properti
adm
absorpt
distribut
metabol
excret
data
predict
lack
main
toxic
risk
howev
drug
like
score
must
increas
virtual
experiment
studi
orient
develop
consist
candid
experiment
preclin
toxic
anticanc
assay
carri
